Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints - MeiraGTx Hldgs ( NASDAQ:MGTX )

3 days ago

On Tuesday, MeiraGTx Holdings plc MGTX released topline data from its clinical bridging study of AAV-GAD for Parkinson's disease, MGT-GAD-025. MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx at its ...

Ticker	Sentiment	Impact
MGTX	Neutral	37 %